Possible bee venom shortage in second half of 2017
Feb 27, 2017:
The ALK bee venom manufacturing facility recently failed a FDA inspection. ALK is therefore currently unable to supply bee venom to the US.
In Australia and New Zealand the Albey brand of bee venom immunotherapy is used, which is distributed by Stallergenes Greer. The manufacturer of the venom used in the Albey products is now facing supply pressures in the US in order to make up the shortfall arising from the non-availability of the ALK bee venom product. This could result in a temporary reduced supply to international consumers including Australia and New Zealand.
It is therefore recommended that patients who are on maintenance bee venom immunotherapy should contact their GP to seek advice from the Allergy/Immunology specialist who initiated the treatment course to discuss options.